Date: 2014-12-18
Type of information: Nomination
Compound: member of the board of directors
Company: Alnylam Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 18, 2014, Alnylam Pharmaceuticals announced the election of Michael W. Bonney to its Board of Directors. Mr. Bonney has served as Chief Executive Officer of Cubist Pharmaceuticals and as a member of its Board of Directors since June 2003 . His experience prior to that includes leadership positions in successful biotech and pharmaceutical companies including Biogen Idec and Zeneca Pharmaceuticals (now AstraZeneca). Michael W. Bonney has served as the Chief Executive Officer of Cubist Pharmaceuticals and as a member of its Board of Directors since June 2003 . He is retiring from his CEO position and transitioning to non-executive Chair of the Board effective December 31, 2014 . From January 2002 to June 2003 , he served as Cubist\'s President and Chief Operating Officer. From 1995 to 2001, Mike held various positions of increasing responsibility at Biogen, including Vice President, Sales and Marketing from 1999 to 2001. While at Biogen, he built the commercial infrastructure for the launch of Avonex. Prior to that, Mike held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals , ending his 11-year career there serving as National Business Director.
Financial terms:
Latest news:
Is general: Yes
